WEST DES MOINES, IA - (NewMediaWire) - August 20, 2015 - Spotlight Innovation Inc. (OTCQB: STLT) announces today that the Company will be a presenter at the SeeThruEquity Fall Microcap Investor Conference to be held at Convene Grand Central in the heart of midtown Manhattan, New York, NY, on September 10, 2015.
As a presenter at the conference, Spotlight Innovation CEO Cristopher Grunewald will showcase the Company and its two subsidiary companies, Celtic Biotech Iowa, Inc., and Memcine Pharmaceuticals, Inc., in a 30-minute presentation, and will attend 1-on-1 meetings with scheduled investors. The conference allows for networking with a variety of attendees including institutional investors, equity research analysts, private client brokers, and the media.
Cristopher Grunewald, President and CEO of Spotlight Innovation, said, "This conference is an outstanding opportunity to connect with investors looking for distinctive opportunities like ours. I am looking forward to cultivating relationships with conference attendees, investors and industry professionals alike."
Celtic Biotech is developing therapies for solid cancers utilizing compounds derived from snake venoms. Memcine Pharmaceuticals is working to enhance vaccine efficacy utilizing its Immunoplex™ platform technology, which uses the body's naturally occurring targeting system to deliver vaccine components. To receive a Spotlight Innovation information kit or to schedule a meeting with Cristopher Grunewald, contact Rudy Barrio at DresnerAllenCaron by calling 1-212-691-8087 or sending an email to email@example.com.
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) identifies, acquires and incubates companies that have unique intellectual property (IP) in the medical sector. The Company has relationships with the nation's leading academic and institutional IP developers, and locates promising IP technologies with potential for market share capture. With strong support, development, resources and strategic planning expertise, we believe we can develop IP that will have a positive effect on healthcare. We partner with proven sector leaders on commercialization once technologies are fully developed. Additional information available at www.spotlightinnovation.com.
About Celtic Biotech Iowa, Inc.
Celtic Biotech Iowa, Inc., a subsidiary of Spotlight Innovation Inc., is developing novel, clinical trial-phase products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality-of-life for cancer patients. Additional information available at www.celticbiotech.com.
About Memcine Pharmaceuticals, Inc.
Memcine Pharmaceuticals, Inc. is an early-stage biotech company focused on enhancing vaccine efficacy to improve human and animal health globally. Memcine's Immunoplex™ technology platform uses the body's naturally occurring targeting system to deliver vaccine components. The current portfolio of potential infectious disease vaccine targets includes influenza, HepB, and Ebola. Memcine Pharmaceuticals has also conducted pre-clinical experiments in a mouse model of breast cancer, where the vaccine technology showed considerable promise as a therapeutic treatment. Additional information available at www.memcine.com.
Forward Looking Statements
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.